Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)
89Zr-DFOsq-olaratumab · 1 trial · 2 indications
Number of Adverse events (AEs)
Measurement of absorbed radiation doses to organs.
Measurement of absorbed radiation doses to tumour(s) and whole body.
Measure the antibody concentration at each timepoint to determine a PK curve.
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | One Injection of 89Zr-TLX300-CDx |
| Part B | EXPERIMENTAL | One Injection of 89Zr-TLX300-CDx |
| Part C | EXPERIMENTAL | One Injection of 89Zr-TLX300-CDx |
| Name | Type | Description |
|---|---|---|
| 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx) | DRUG | Single administration of 89Zr-TLX300-CDx |
INCLUSION CRITERIA: 1. ≥18 years of age at the time of signing the informed consent. 2. Histologically confirmed diagnosis of soft tissue sarcoma (STS). Patients with indications other than STS, that could be PDGFRα positive, will also be considered This would be subject to case-by-case approval by...
89Zr-DFOsq-olaratumab is an investigational monoclonal antibody imaging agent being developed by Telix Pharmaceuticals Limited for soft tissue sarcoma. It combines the antibody olaratumab with the radioisotope zirconium-89 to visualize PDGFR alpha positive tumors. It is currently in Phase 1 clinical development and is not approved for commercial use.
89Zr-DFOsq-olaratumab is being studied for use in soft tissue sarcoma and other PDGFR alpha positive solid tumors. It is designed as a diagnostic imaging agent to help identify and characterize tumors that express PDGFR alpha. The research is in Phase 1 and the drug has not been approved for any indication.
89Zr-DFOsq-olaratumab targets PDGFR alpha, a receptor tyrosine kinase found on certain tumor cells. The antibody component olaratumab binds to PDGFR alpha, and the attached zirconium-89 radioisotope allows positron emission tomography imaging of PDGFR alpha expression in tumors. This targeting mechanism is under investigation in a Phase 1 trial.
89Zr-DFOsq-olaratumab is being developed by Telix Pharmaceuticals Limited, which trades under the ticker TLX. Telix is an Australian radiopharmaceutical company focused on diagnostic and therapeutic products. The company is sponsoring the Phase 1 clinical trial of this imaging agent.
89Zr-DFOsq-olaratumab is in Phase 1 clinical development. It is an investigational product and has not been approved by the FDA or any regulatory agency. The Phase 1 trial is currently recruiting participants and is designed to evaluate dosimetry in patients with PDGFR alpha positive solid tumors and soft tissue sarcoma.
89Zr-DFOsq-olaratumab is being studied in one clinical trial, NCT06537596, titled '89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue Sarcoma.' This Phase 1 trial is recruiting up to 50 participants in Australia and is currently active.
Yes, 89Zr-DFOsq-olaratumab is also known as 89Zr-TLX300-CDx. Both names refer to the same investigational imaging agent developed by Telix Pharmaceuticals. The 'CDx' suffix indicates its intended use as a companion diagnostic, while 'DFOsq' refers to the linker chemistry used to attach zirconium-89 to the antibody.